EBOS Group Limited (ASX:EBO)
Australia · Delayed Price · Currency is AUD | Market Cap | 3.65B -46.3% |
| Revenue (ttm) | 13.04B +3.5% |
| Net Income | 229.47M -6.7% |
| EPS | 1.13 -11.1% |
| Shares Out | n/a |
| PE Ratio | 15.90 |
| Forward PE | 13.97 |
| Dividend | 1.08 (6.23%) |
| Ex-Dividend Date | Mar 5, 2026 |
| Volume | 105,680 |
| Average Volume | 115,680 |
| Open | 17.39 |
| Previous Close | 17.28 |
| Day's Range | 17.17 - 17.55 |
| 52-Week Range | 17.09 - 38.23 |
| Beta | 0.23 |
| RSI | 35.47 |
| Earnings Date | May 25, 2026 |
About EBOS Group
EBOS Group Limited engages in the marketing, wholesale, and distribution of healthcare, medical, pharmaceutical, and animal care products in Australia, Southeast Asia, and New Zealand. It operates through Healthcare and Animal Care segments. The company provides healthcare logistics; medication management solutions; pharmacy management software; loyalty, generics, compliance, business intelligence, and store software services; and health communications, programs, and consultancy services. It also offers community based health care services and ... [Read more]
Financial Performance
In fiscal year 2025, EBOS Group's revenue was 12.27 billion, a decrease of -6.99% compared to the previous year's 13.19 billion. Earnings were 215.14 million, a decrease of -20.77%.
Financial StatementsNews
EBOS Group Issues Update To FY26 Earnings Outlook
(RTTNews) - EBOS Group (EBO.AX) issued an update on the impact of elevated fuel prices and broader energy cost pressures on the Group's fiscal 2026 earnings outlook. Based on current assumptions for t...
Ebos Group Ltd (ASX:EBO) Half Year 2026 Earnings Call Highlights: Strong Revenue Growth Amidst ...
Ebos Group Ltd (ASX:EBO) Half Year 2026 Earnings Call Highlights: Strong Revenue Growth Amidst Strategic Investments
Half Year 2026 EBOS Group Ltd Earnings Call Transcript
Half Year 2026 EBOS Group Ltd Earnings Call Transcript
EBOS Group Earnings Call Transcript: H1 2026
Revenue grew 13% to AUD 6.8 billion, with underlying EBITDA up 3.2% and strong segment performance in Healthcare and Animal Care. FY 2026 guidance is reaffirmed, with margin and cash flow improvements expected as the DC Renewal Program nears completion and productivity rises.
LARGE CAP INTERNATIONAL PORTFOLIO Buys Shares of Ebos Group Ltd (EBO)
LARGE CAP INTERNATIONAL PORTFOLIO Buys Shares of Ebos Group Ltd (EBO)
EBOS Group Transcript: AGM 2025
The meeting reviewed strong revenue growth and strategic investments, but addressed challenges from the loss of a major contract, margin pressures, and a significant share price decline. Executive incentives were updated to better align with shareholder interests, and all board resolutions proceeded to vote.
EBOS Group Earnings Call Transcript: H2 2025
Solid organic growth and strategic acquisitions drove a 12% revenue and 7.5% EBITDA increase, despite the loss of a major contract. Competitive pressures and soft consumer demand persist, but guidance targets 7% EBITDA growth in FY 2026, with continued investment in infrastructure and cost management.
UBS launches $NZ217m EBOS Group placement to fund acquisitions
New shares were priced at $NZ36.65 – a 5 per cent discount to the last close price.
Ebos Group Ltd (EBOSF) (Q1 2025) Earnings Call Highlights: Strong Revenue Growth Amid Strategic ...
Ebos Group Ltd (EBOSF) (Q1 2025) Earnings Call Highlights: Strong Revenue Growth Amid Strategic Investments
Half Year 2025 EBOS Group Ltd Earnings Call Transcript
Half Year 2025 EBOS Group Ltd Earnings Call Transcript
EBOS Group Earnings Call Transcript: H1 2025
Underlying revenue rose 9.5% and EBITDA 7% in H1 FY25, with strong growth in healthcare and animal care segments, cost savings, and new customer wins offsetting the loss of the Chemist Warehouse contract. FY25 EBITDA guidance of AUD 575–600 million was reiterated.
EBOS Group Transcript: AGM 2024
Strong financial growth was reported, with revenue surpassing AUD 13 billion and dividends up 7.7%. Board renewal progressed, ESG initiatives advanced, and strategic acquisitions continued. All resolutions were presented without significant opposition, and management expressed confidence in future growth.
Ebos Group Ltd (EBOSY) (Q4 2024) Earnings Call Transcript Highlights: Strong Revenue and EBITDA ...
Ebos Group Ltd (EBOSY) (Q4 2024) Earnings Call Transcript Highlights: Strong Revenue and EBITDA Growth Amid Strategic Investments
Full Year 2024 EBOS Group Ltd Earnings Call Transcript
Full Year 2024 EBOS Group Ltd Earnings Call Transcript
EBOS Group Earnings Call Transcript: H2 2024
Revenue grew 7.8% to AUD 13.2B, underlying EBITDA rose 7.3% to AUD 624M, and EPS increased 6.8%. FY 2025 guidance targets AUD 575–600M EBITDA, with cost savings and new pharmacy revenues expected to offset the end of the Chemist Warehouse contract.